Raynaud phenomenon in three patients with acquired immune deficiency syndrome-related Kaposi sarcoma treated with bleomycin

C F von Gunten; E L Roth; J H Von Roenn

doi:10.1002/1097-0142(19930915)72:6<2004::aid-cncr2820720635>3.0.co;2-5

Raynaud phenomenon in three patients with acquired immune deficiency syndrome-related Kaposi sarcoma treated with bleomycin

Cancer. 1993 Sep 15;72(6):2004-6. doi: 10.1002/1097-0142(19930915)72:6<2004::aid-cncr2820720635>3.0.co;2-5.

Authors

C F von Gunten¹, E L Roth, J H Von Roenn

Affiliation

¹ Northwestern University, Chicago, Illinois 60611.

Abstract

The authors report three cases of Raynaud phenomenon that developed during doxorubicin, bleomycin, and vincristine (ABV) therapy for acquired immune deficiency syndrome (AIDS)-related Kaposi sarcoma. Although Raynaud phenomenon is well documented as a side effect of bleomycin, vinblastine, and cisplatin chemotherapy for germ cell neoplasms, it has not been widely documented in patients with AIDS.

Publication types

Case Reports

MeSH terms

Acquired Immunodeficiency Syndrome / complications*
Adult
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Bleomycin / administration & dosage
Bleomycin / adverse effects*
Doxorubicin / administration & dosage
Doxorubicin / adverse effects
HIV Seropositivity / complications
Humans
Male
Raynaud Disease / chemically induced*
Sarcoma, Kaposi / complications*
Sarcoma, Kaposi / drug therapy
Vinblastine / administration & dosage
Vinblastine / adverse effects

Substances

Bleomycin
Vinblastine
Doxorubicin

Supplementary concepts

VBA protocol